Welcome to our dedicated page for LXRP news (Ticker: LXRP), a resource for investors and traders seeking the latest updates and insights on LXRP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LXRP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LXRP's position in the market.
Lexaria Bioscience Corp. (NASDAQ: LEXX) has announced a podcast titled “Hypertension: The Silent Killer Making Loud Noise for Investors.” The global anti-hypertensive drugs market is projected to grow from $24.37 billion in 2021 to $27.81 billion by 2025, highlighting a significant market opportunity. Lexaria's proprietary drug-delivery technology, DehydraTECH™, enhances the absorption of fat-soluble drugs and has applications across various product formats. With a market cap of around $35 million, Lexaria aims to capitalize on this growing sector and has a robust intellectual property portfolio with 21 patents granted.
Lexaria Bioscience Corp. (NASDAQ: LEXX) is featured in an editorial by NetworkNewsWire highlighting the significant issue of hypertension in America, affecting 108 million adults. Despite the variety of treatment options, only 25% of individuals have their condition under control, leading to increased risks for heart disease and stroke. Lexaria's proprietary DehydraTECH™ technology shows promise in delivering effective treatments for hypertension without significant side effects, aiming to compete in a lucrative market. The company holds 21 patents and has over 50 pending globally.
Lexaria Bioscience Corp. (NASDAQ: LEXX) has highlighted its innovative DehydraTECH technology, aimed at revolutionizing drug delivery by enhancing bioavailability and reducing onset time for various medications. This platform could significantly impact the management of cardiovascular diseases, a principal cause of mortality in the U.S. The company holds 21 patents and has over 50 pending globally, indicating a strong intellectual property position. They have licensed their technology to major firms for the development of smokeless nicotine products and cannabinoid-based consumables.
Lexaria Bioscience (NASDAQ: LEXX) was featured in an editorial by NetworkNewsWire, highlighting its role in addressing cardiovascular disease, a leading cause of mortality. The CDC reports about 108 million Americans have hypertension, with only 24% under control. Lexaria’s patented DehydraTECH™ drug delivery enhances the absorption of active pharmaceutical ingredients, potentially revolutionizing treatments. The technology has proven effective in increasing cannabinoid bioabsorption by up to 10 times and is intended for dietary products, anti-viral drugs, and more, reflecting Lexaria’s commitment to innovate in the pharmaceutical space.
Lexaria Bioscience Corp. (OTCQX:LXRP) has finalized the sale of its non-pharmaceutical THC-related assets for $3,850,000 to Hill Street Beverage Company. The transaction includes $350,000 in cash, shares amounting to $500,000, and a $2,000,000 promissory note. Lexaria retains its DehydraTECH technology for pharmaceutical applications while enabling Hill Street to utilize it for THC-related products. This sale is pivotal as Lexaria aims for a potential listing on a national US securities exchange.
Lexaria Bioscience Corp. announces participation in four investor conferences: Benzinga Global Small Cap Conference on December 8, LD Micro Main Event on December 15, and the H.C. Wainwright BioConnect and Virtual Biotech Showcase on January 11-14, 2021. CEO Chris Bunka will present Lexaria's DehydraTECH™ technology, which enhances drug delivery for treatments against HIV/AIDS and potential applications for COVID-19. The company aims to improve its focus on pharmaceutical markets and plans to discuss recent asset sales for uplisting to a national exchange.
Lexaria Bioscience Corp. (LXRP) announced significant advancements in its DehydraTECH technology, enhancing the delivery of antiviral drugs. In studies, the technology improved the delivery of darunavir and efavirenz, with bioavailability increases of up to 54% observed. Both drugs are crucial in treating HIV/AIDS and are under investigation for COVID-19 treatment. The study showed excellent safety and tolerability in animal subjects, paving the way for further investigations into antiviral drug delivery. Lexaria plans expanded studies starting January 2021 to explore its technology's potential in additional antiviral applications.
Lexaria Bioscience Corp. has entered into a definitive agreement to sell non-core THC-related assets for $3.85 million CDN (approximately US$2.85 million) to Hill Street Beverage Company. The deal includes $350,000 in cash, $2 million through a promissory note, and $1.5 million in Hill Street shares. Lexaria retains ownership of its DehydraTECH technology and continues to focus on pharmaceutical applications. This strategic move is part of Lexaria's plan to prepare for a listing on a US national securities exchange, with the sale expected to close within 30 days, pending regulatory approvals.
Lexaria Bioscience Corp. (OTCQX:LXRP) is shifting its focus for 2021 towards four core segments: heart disease treatments with CBD, non-combusted nicotine delivery, improved antiviral drug delivery, and CBD from hemp. The company aims to leverage its patented DehydraTECH technology to enhance drug absorption significantly, evidenced by previous studies. The heart disease drug market is projected to grow from $47.29 billion to $63.96 billion by 2026. Lexaria is also expanding patent protections globally as it collaborates with major pharmaceutical and tobacco firms.
Lexaria Bioscience Corp. (OTCQX:LXRP) announced significant growth expectations for its DehydraTECH-enabled CBD powders. The company reported processing approximately 4.2 million servings by October 21, 2020, surpassing initial estimates of 4.4 million for Q1 2021. Increased demand has led to revised projections of over 8.0 million servings this quarter, representing a 500% increase from Q4 2020. Lexaria anticipates producing at least 56 million servings in 2021, driven by ongoing orders. The company cautions that it cannot control third-party fulfillment of business expectations.
